Suchergebnisse

PubPharm (730)

91

Nijkamp and Parnham's Principles of Immunopharmacology

Erschienen: Cham, Springer International Publishing, 2019

Springer eBook Collection

4th ed. 2019.

von Parnham, M. | Nijkamp, F. | Rossi, A.

92

Maternal immunization

Erschienen: [S.l.], Academic Press, 2019

von Jones, C. | Leuridan, E. | Nunes, M.

93

Cancer Drug Delivery Systems Based on the Tumor Microenvironment

Erschienen: Tokyo, Springer Japan, 2019

Springer eBook Collection

1st ed. 2019.

von Matsumura, Y. | Tarin, D.

94

Pathogenicity and Drug Resistance of Human Pathogens : Mechanisms and Novel Approaches

Erschienen: Singapore, Springer Singapore, 2019

Springer eBook Collection

1st ed. 2019.

von Hameed, S. | Fatima, Z.

95

Drugs for pregnant and lactating women

Erschienen: Philadelphia, PA, Elsevier, [2019]

Third edition

von Weiner, C. | Mason, C.

96

Nanocarriers for brain targeting : principles and applications

Erschienen: Toronto, Apple Academic Press,, 2019

von Keservani, R. | Sharma, A. | Kesharwani, R.

97

Hensley's practical approach to cardiothoracic anesthesia

Erschienen: Philadelphia, Wolters Kluwer/Lippincott Williams & Wilkins Health, [2019]

Sixth edition

von Shaw, A. | Gravlee, G. | Bartels, K.

98

Clinical review report : (Novo nordisk Canada Inc.)Insulin degludec and liraglutide injection (Xultophy)

Erschienen: Ottawa (ON), CADTH, December 2019

CADTH common drug review

Version: final (with redactions).

99

Pharmacoeconomic review report : Insulin degludec and liraglutide injection (Xultophy) (Novo Nordisk Canada Inc.)

Erschienen: Ottawa (ON), CADTH, December 2019

CADTH common drug review

Version: Final (with redactions).

100

CADTH Canadian Drug Expert Committee recommendation : indication : adjunct to lifestyle modifications, for the once-daily treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily), do not provide adequate glycemic controlInsulin degludec and liraglutide (Xultophy -- Novo Nordisk Canada Inc.)

Erschienen: Ottawa (ON), CADTH, October 2019

CADTH common drug review

Version: 1.0.